Investors Target ARS Pharmaceuticals Over Alleged Misleading Coverage Claims

The lawsuit alleges that ARS Pharmaceuticals provided investors with inaccurate information concerning the rollout of expanded insurance coverage for its epinephrine nasal spray, neffy, specifically through CVS Caremark. Company statements had expressed confidence that this coverage would commence on July 1, 2026, in time for the critical summer and back-to-school allergy seasons. According to the complaint, these assurances were disseminated while the company concealed material adverse facts regarding the actual expected timeline for the coverage agreement.

These disclosures allegedly led to shareholders purchasing securities at artificially inflated prices. As the true nature of the insurance timeline emerged, the market valuation adjusted, resulting in financial losses for investors. Those seeking to serve as lead plaintiff in the action must file a motion with the Court by October 5, 2026. Participation in any potential recovery does not require serving as a lead plaintiff, and investors retain the right to select their own legal representation.